about
Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routesDevelopment of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic.Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza virusesNasal vaccine innovation.Antigen trafficking and accessory cell function in respiratory epithelial cells.Functions of tonsils in the mucosal immune system of the upper respiratory tract using a novel animal model, Suncus murinus.Current status of a mucosal vaccine against dental caries.Protective salivary immunoglobulin A responses against Streptococcus mutans infection after intranasal immunization with S. mutans antigen I/II coupled to the B subunit of cholera toxinBaculovirus-based nasal drop vaccine confers complete protection against malaria by natural boosting of vaccine-induced antibodies in miceSystemic antibodies can inhibit mouse mammary tumor virus-driven superantigen response in mucosa-associated lymphoid tissues.Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers.Intranasal antibody prophylaxis for protection against viral disease.Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization.Evaluation of mucoadhesive PLGA microparticles for nasal immunization.Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissueAntigen presentation and stimulation of the immune system in human airways.Mucosal immunity and tolerance: relevance to vaccine development.Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes.Antigen-presenting cells in nasal allergy.CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment.Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodesNasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice.Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A.Characterization of inflammatory responses during intranasal colonization with Streptococcus pneumoniae.Histopathologic approaches to detect changes indicative of immunotoxicity.A controlled clinical study of the effect of nasal immunization with a Streptococcus mutans antigen alone or incorporated into liposomes on induction of immune responsesMutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIbConstruction and characterization of a Salmonella enterica serovar typhimurium clone expressing a salivary adhesin of Streptococcus mutans under control of the anaerobically inducible nirB promoterIntranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii.Reduced virulence of a Bordetella bronchiseptica siderophore mutant in neonatal swine.Facilitated intranasal induction of mucosal and systemic immunity to mutans streptococcal glucosyltransferase peptide vaccines.Nasal tolerance induction as a potential means of immunotherapy for autoimmune diseases: implications for clinical medicine.Influence of intravenous anesthesia on mucosal and systemic antibody responses to nasal vaccinesProbing local innate immune responses after mucosal immunisationInduction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixedHealth risks associated with inhaled nasal toxicants.Immunological effects of interleukin-2 therapy in human immunodeficiency virus-positive subjectsTrachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles.Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit.
P2860
Q22241377-2E6B67FB-DE4D-4CCF-9C55-27181815AF88Q30360869-ABAC0718-96A7-4DDD-B6F5-D24A62D95D61Q30377017-414DA9EA-66C0-4679-AF4F-EF9F7FB125BEQ30395810-8D1916D0-1A35-451B-8F41-11EFC957A19AQ30759145-A67A49F8-4235-4046-8F4B-F7EBDCBB84E3Q33260817-AD6D9B5E-F5E8-443E-BA06-29881DB3476AQ33594600-A8EC4506-F3EF-4D17-8675-CD2A14D67011Q33596220-8E518D3D-38E4-47FE-9ECA-4520A7C7642FQ33613859-3E3B5529-7B52-40A7-8452-10FECB324894Q33642634-757D06BD-48D2-44EB-AD22-FC8A756D8BA4Q33650384-37A0306D-DE26-46C8-A565-6918639FB19CQ33683058-5D7639F8-E151-43D6-BEE6-C10FEEAAF25BQ33725145-25D2820E-2B7D-438F-9A10-91896EBA9342Q33749489-4A3C9A61-9B26-485F-8AB8-BA6673FCCD05Q33769366-59138BE2-A277-4258-8C94-C1A9065AD0FAQ33775585-0E268CB1-98FD-4646-8B46-C9DD31ED2C78Q33776172-CE0E7E6D-DDBA-4FBE-8BAB-F61082CF2299Q33784161-D4D66234-118E-469F-8FAE-EC094989F4DAQ33799245-24427615-A466-4002-94BD-FCBA145B9134Q33801890-3A1A83DA-EEB1-404B-B160-2DB9D25F7A20Q33822614-1FABDC0A-0D62-4AAC-A5A7-F1EA9A8EEE9EQ33852342-22AB4410-7635-43B2-B11F-58CE92D3FD56Q33866797-0D12EA02-5D9B-416B-8467-237CB54BDA54Q33872655-2E9CBEFE-F624-456F-A60E-9EA76370E5A2Q33947672-ABC7B6D0-E193-443D-8B8F-848C96FBA848Q34000204-16D155EF-1B51-4388-AFBA-BB5E65B38198Q34002672-C25FDCA3-9F56-4D79-9B1A-B229019C5783Q34003066-3C4279C1-4058-469B-B1B9-2217894B2931Q34003662-833DD8DE-07CE-4A50-8158-8256690A4222Q34006385-E5220399-C554-48A3-9F6B-3941D3DB382DQ34006713-BBA6F8AF-1C81-464D-ADF1-8574DAE8064BQ34008465-27EFADB6-BAB9-4112-918A-E3BED34D6882Q34106906-741EBB30-C48E-4A23-B5BF-20EC9E31E66FQ34131862-0608A1DC-D2D9-4F63-A1B3-82BAE96FE4B4Q34154378-A7FB9853-470E-4A95-A52D-1813744CAF2BQ34194667-56A2F952-205C-451C-A08E-F0EFBB39C07EQ34281120-53B473AC-BE2D-4336-B8DA-7A60539956EEQ34293966-AAFDF68F-B31B-4E14-B934-8C0EDC0DB686Q34353473-DAD51189-BF0F-4866-8D21-2024B8C80CBFQ34522325-D7FB0DF4-70B0-4033-AD36-D7BC9767BE92
P2860
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
The role of nasopharyngeal lymphoid tissue.
@ast
The role of nasopharyngeal lymphoid tissue.
@en
type
label
The role of nasopharyngeal lymphoid tissue.
@ast
The role of nasopharyngeal lymphoid tissue.
@en
prefLabel
The role of nasopharyngeal lymphoid tissue.
@ast
The role of nasopharyngeal lymphoid tissue.
@en
P2093
P1433
P1476
The role of nasopharyngeal lymphoid tissue.
@en
P2093
Biewenga J
Duijvestijn AM
Hameleers DM
Koornstra PJ
van Breda Vriesman PJ
P304
P356
10.1016/0167-5699(92)90158-4
P577
1992-06-01T00:00:00Z